Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Staphylococcal Endocarditis-Reply

Treatment of Staphylococcal Endocarditis-Reply Our intent in writing the LETTER TO THE EDITOR was to criticize Bryant and Alford's extrapolation from one patient with S aureus endocarditis who clearly relapsed after cefazolin therapy and one who was a very questionable failure to a general prohibition about use of this agent in S aureus endocarditis. We also questioned the validity of their second case and asked for studies of antibacterial activity in serum (usually considered standard procedure in managing endocarditis) to better evaluate their cases. These are not forthcoming in their answer to our letter. We also pointed out that S aureus endocarditis is a difficult disease to treat and that failures have been reported with every antistaphylococcal agent that has been evaluated. We certainly did not question the need to report both favorable and unfavorable results but only their interpretations. In the preceding letter, Bryant and Alford point out that there is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Treatment of Staphylococcal Endocarditis-Reply

JAMA , Volume 239 (12) – Mar 20, 1978

Loading next page...
 
/lp/american-medical-association/treatment-of-staphylococcal-endocarditis-reply-rVU6cPAXJb

References (3)

Publisher
American Medical Association
Copyright
Copyright © 1978 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1978.03280390026005
Publisher site
See Article on Publisher Site

Abstract

Our intent in writing the LETTER TO THE EDITOR was to criticize Bryant and Alford's extrapolation from one patient with S aureus endocarditis who clearly relapsed after cefazolin therapy and one who was a very questionable failure to a general prohibition about use of this agent in S aureus endocarditis. We also questioned the validity of their second case and asked for studies of antibacterial activity in serum (usually considered standard procedure in managing endocarditis) to better evaluate their cases. These are not forthcoming in their answer to our letter. We also pointed out that S aureus endocarditis is a difficult disease to treat and that failures have been reported with every antistaphylococcal agent that has been evaluated. We certainly did not question the need to report both favorable and unfavorable results but only their interpretations. In the preceding letter, Bryant and Alford point out that there is

Journal

JAMAAmerican Medical Association

Published: Mar 20, 1978

There are no references for this article.